Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; A preliminary clinical study
JOURNAL OF BUON, cilt.16, sa.4, ss.759-764, 2011 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 16 Sayı: 4
- Basım Tarihi: 2011
- Dergi Adı: JOURNAL OF BUON
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.759-764
- Çukurova Üniversitesi Adresli: Evet
Özet
Purpose: Sorafenib has been found to have significant clinical activity against hepatocellular carcinoma (HCC). Hand-foot skin syndrome (HFS) has been described with the usage of sorafenib. It is a dose-limiting toxicity and may lead to compromised efficacy because of dose reduction.